Physician profile
Thomas A Bragg
NPI 1790891885
$5,491.56
in general payments reported to CMS, 2019-2025
34 companies · $599 in 2025
The $599 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $728 · 2020: $457 · 2021: $836 · 2022: $851 · 2023: $937 · 2024: $1,083 · 2025: $599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,519 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,519.18 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,145.32 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $617.29 | 2021-2024 | Vraylar |
| Janssen Pharmaceuticals, INC | $519.50 | 2019-2024 | Spravato |
| Teva Pharmaceuticals USA, INC. | $518.30 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Lilly USA, LLC | $216.63 | 2019-2024 | Zepbound, Mounjaro |
| Pfizer INC. | $207.99 | 2019-2021 | |
| Amarin Pharma, INC. | $196.70 | 2019-2020 | |
| Nevro Corp. | $189.81 | 2022-2024 | Senza |
| Grifols USA, LLC | $172.59 | 2019-2023 | Prolastin-C Liquid |
| Novartis Pharmaceuticals Corporation | $161.09 | 2019-2023 | |
| Alkermes, INC. | $146.31 | 2024 | Lybalvi, Aristada |
| Novo Nordisk INC | $131.60 | 2021-2025 | Ozempic, Rybelsus |
| Phathom Pharmaceuticals, INC. | $127.99 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.15 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $121.05 | 2022-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $108.69 | 2024 | Rexulti |
| Sk Life Science, INC. | $101.04 | 2022 | |
| Merck Sharp & Dohme LLC | $100.76 | 2019-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Sunovion Pharmaceuticals INC. | $79.41 | 2020-2022 | |
| Abbott Laboratories | $68.50 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Exact Sciences Corporation | $65.47 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $50.62 | 2022-2023 | Eliquis |
| Globus Medical, INC. | $50.18 | 2025 | Senza |
| Allergan, INC. | $39.14 | 2020 | |
| Mylan Specialty L.P. | $37.15 | 2023-2024 | Yupelri |
| Almatica Pharma LLC | $36.15 | 2021-2022 | |
| Amgen INC. | $32.56 | 2022-2023 | Otezla, Repatha |
| Dexcom, INC. | $27.66 | 2023 | Dexcom G6 Transmitter |
| Ironshore Pharmaceuticals INC. | $24.80 | 2019 | |
| Lundbeck LLC | $17.06 | 2024 | Rexulti |
| Sobi, INC | $16.57 | 2022 | |
| Glaxosmithkline, LLC. | $13.17 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $12.50 | 2021 | |
| Sanofi-Aventis U.S. LLC | $10.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Bragg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.